Latest & greatest articles for macrolides

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on macrolides or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on macrolides and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for macrolides

1. Prescription of macrolides vs penicillin during pregnancy was linked to major malformations in offspring. (Abstract)

Prescription of macrolides vs penicillin during pregnancy was linked to major malformations in offspring. Fan H, Gilbert R, O'Callaghan F, Li L. Associations between macrolide antibiotics prescribing during pregnancy and adverse child outcomes in the UK: population based cohort study. BMJ. 2020;368:m331. 32075790.

2020 Annals of Internal Medicine

2. RETRACTED: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Full Text available with Trip Pro

RETRACTED: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Hydroxychloroquine or chloroquine, often in combination with a second-generation macrolide, are being widely used for treatment of COVID-19, despite no conclusive evidence of their benefit. Although generally safe when used for approved indications such as autoimmune disease or malaria, the safety and benefit of these treatment regimens are poorly evaluated (...) in COVID-19.We did a multinational registry analysis of the use of hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19. The registry comprised data from 671 hospitals in six continents. We included patients hospitalised between Dec 20, 2019, and April 14, 2020, with a positive laboratory finding for SARS-CoV-2. Patients who received one of the treatments of interest within 48 h of diagnosis were included in one of four treatment groups (chloroquine alone, chloroquine

2020 Lancet

3. BTS Guideline for Long Term Macrolide Use

BTS Guideline for Long Term Macrolide Use British Thoracic Society guideline for the use of long- term macrolides in adults with respiratory disease David Smith, 1 Ingrid Du Rand, 2 Charlotte Louise Addy, 3 Timothy Collyns, 4 Simon Paul Hart , 5 Philip J Mitchelmore , 6,7 Najib M Rahman, 8 Ravijyot Saggu 9 BTS Guideline To cite: Smith D, Du Rand I, Addy CL, et al. Thorax Epub ahead of print: [please include Day Month Year]. doi:10.1136/ thoraxjnl-2019-213929 ? Additional material is published (...) . smith@ nbt. nhs . uk ? http:// dx. doi . org/ 10. 1136/ thor axjnl- 2019- 214039 © Author(s) (or their employer(s)) 2020. No commercial re- use. See rights and permissions. Published by BMJ. SUMMARY OF RECOMMENDATIONS AND GOOD PRACTICE POINTS Asthma Recommendations ? Oral macrolide therapy could be considered to reduce exacerbation frequency in adults (50–70 years), with ongoing symptoms despite >80% adherence to high- dose inhaled steroids (>800 µg/day) and at least one exacerbation requiring oral

2020 British Thoracic Society

4. British Thoracic Society guideline for the use of long-term macrolides in adults with respiratory disease Full Text available with Trip Pro

British Thoracic Society guideline for the use of long-term macrolides in adults with respiratory disease British Thoracic Society Guideline for the Use of Long-Term Macrolides in Adults With Respiratory Disease - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. National Institutes of Health National Library of Medicine National (...) Actions . 2020 May;75(5):370-404. doi: 10.1136/thoraxjnl-2019-213929. Epub 2020 Apr 17. British Thoracic Society Guideline for the Use of Long-Term Macrolides in Adults With Respiratory Disease , , , , , , , Affiliations Expand Affiliations 1 North Bristol Lung Centre, Southmead Hospital, Bristol, UK david.smith@nbt.nhs.uk. 2 Respiratory, Wye Valley NHS Trust, Hereford, UK. 3 Centre for Medical Education, Queens University Belfast, Regional Respiratory Centre, Belfast City Hospital, Belfast, UK. 4

2020 EvidenceUpdates

5. Associations between macrolide antibiotics prescribing during pregnancy and adverse child outcomes in the UK: population based cohort study. Full Text available with Trip Pro

Associations between macrolide antibiotics prescribing during pregnancy and adverse child outcomes in the UK: population based cohort study. To assess the association between macrolide antibiotics prescribing during pregnancy and major malformations, cerebral palsy, epilepsy, attention deficit hyperactivity disorder, and autism spectrum disorder in children.Population based cohort study.The UK Clinical Practice Research Datalink.The study cohort included 104 605 children born from 1990 to 2016 (...) whose mothers were prescribed one macrolide monotherapy (erythromycin, clarithromycin, or azithromycin) or one penicillin monotherapy from the fourth gestational week to delivery. Two negative control cohorts consisted of 82 314 children whose mothers were prescribed macrolides or penicillins before conception, and 53 735 children who were siblings of the children in the study cohort.Risks of any major malformations and system specific major malformations (nervous, cardiovascular, gastrointestinal

2020 BMJ

6. What is the evidence for use of macrolide antibiotics for treatment of COVID-19?

What is the evidence for use of macrolide antibiotics for treatment of COVID-19? What is the evidence for use of macrolide antibiotics for treatment of COVID-19? - CEBM CEBM The Centre for Evidence-Based Medicine develops, promotes and disseminates better evidence for healthcare. Navigate this website What is the evidence for use of macrolide antibiotics for treatment of COVID-19? April 28, 2020 Kome Gbinigie and Kerstin Frie On behalf of the Oxford COVID-19 Evidence Service Team Centre (...) for Evidence-Based Medicine, Nuffield Department of Primary Care Health Sciences University of Oxford Correspondence to VERDICT We identified three studies, two in vitro and one in vivo , assessing the use of macrolide antibiotics for the treatment of COVID-19. Each of these studies assessed treatment with azithromycin. The evidence from the in vivo study and one in vitro study suggest a possible synergy between azithromycin and hydroxychloroquine. However, the in vivo study had a small number

2020 Oxford COVID-19 Evidence Service

7. Tailored Helicobacter pylori eradication based on prior intake of macrolide antibiotics allows the use of triple therapy with optimal results in an area with high clarithromycin resistance. Full Text available with Trip Pro

Tailored Helicobacter pylori eradication based on prior intake of macrolide antibiotics allows the use of triple therapy with optimal results in an area with high clarithromycin resistance. the previous intake of macrolide antibiotics is associated with a failure to eradicate Helicobacter pylori (H. pylori) with clarithromycin-containing regimens. However, the standard triple therapy achieves eradication rates of over 90% in patients without a previous use of macrolides in our health area (...) . The aim of this study was to evaluate the efficacy of an H. pylori eradication strategy based on the intake of macrolides by the patient during the previous years.one hundred and sixty-nine patients with H. pylori infection were prospectively included in the study. The electronic medical record of each patient was reviewed at the time of inclusion. Depending on their previous intake of macrolides, patients were assigned to one of two eradication regimens: group A) patients without a previous intake

2019 Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva Controlled trial quality: uncertain

8. Evaluation of severity score-guided approaches to macrolide use in community-acquired pneumonia Full Text available with Trip Pro

Evaluation of severity score-guided approaches to macrolide use in community-acquired pneumonia International guidelines including those in the UK, Japan, Australia and South Africa recommend the avoidance of macrolides in patients with low-severity community-acquired pneumonia (CAP). We hypothesised that severity scores are poor predictors of atypical pneumonia and response to macrolide therapy, and thus, inadequate tools for guiding antibiotic prescriptions.Secondary analysis of four (...) independent prospective CAP datasets was conducted. The predictive values of the CURB-65 and pneumonia severity index (PSI) for clinically important groups of causative pathogens were evaluated. The effect of macrolide use according to risk class was assessed by multivariable analysis. Patients (3297) were evaluated, and the predictive values of CURB-65 and PSI for atypical pathogens were poor (AUC values of 0.37 and 0.42, respectively). No significant differences were noted among the effects of macrolide

2017 EvidenceUpdates

9. Macrolide antibiotics and the risk of ventricular arrhythmia in older adults Full Text available with Trip Pro

Macrolide antibiotics and the risk of ventricular arrhythmia in older adults Many respiratory tract infections are treated with macrolide antibiotics. Regulatory agencies warn that these antibiotics increase the risk of ventricular arrhythmia. We examined the 30-day risk of ventricular arrhythmia and all-cause mortality associated with macrolide antibiotics relative to nonmacrolide antibiotics.We conducted a population-based retrospective cohort study involving older adults (age > 65 yr (...) ) with a new prescription for an oral macrolide antibiotic (azithromycin, clarithromycin or erythromycin) in Ontario from 2002 to 2013. Our primary outcome was a hospital encounter with ventricular arrhythmia within 30 days after a new prescription. Our secondary outcome was 30-day all-cause mortality. We matched patients 1:1 using propensity scores to patients prescribed nonmacrolide antibiotics (amoxicillin, cefuroxime or levofloxacin). We used conditional logistic regression to measure the association

2016 EvidenceUpdates

10. Macrolides for diffuse panbronchiolitis. Full Text available with Trip Pro

Macrolides for diffuse panbronchiolitis. Diffuse panbronchiolitis (DPB) is a chronic airways disease predominantly affecting East Asians. Macrolides, a class of antibiotics, have been used as the main treatment for DPB, based on evidence from retrospective and non-randomised studies.To assess the efficacy and safety of macrolides for DPB.We searched CENTRAL (2014, Issue 6), MEDLINE (1966 to July week 1, 2014), EMBASE (1974 to July 2014), Chinese Biomedical Literature Database (CBM) (1978 (...) to July 2014), China National Knowledge Infrastructure (CNKI) (1974 to July 2014), KoreaMed (1997 to July 2014) and Database of Japana Centra Revuo Medicina (1983 to July 2014).Randomised controlled trials (RCTs) or quasi-RCTs assessing the effect of macrolides for DPB.Two review authors independently assessed study quality and subsequent risk of bias according to The Cochrane Collaboration's tool for assessing risk of bias. The primary outcomes were five-year survival rate, lung function and clinical

2015 Cochrane

11. Cohort study: Balancing competing risks: perinatal exposure to macrolides increases the risk of infantile hypertrophic pyloric stenosis Full Text available with Trip Pro

Cohort study: Balancing competing risks: perinatal exposure to macrolides increases the risk of infantile hypertrophic pyloric stenosis Balancing competing risks: perinatal exposure to macrolides increases the risk of infantile hypertrophic pyloric stenosis | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our (...) . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Balancing competing risks: perinatal exposure to macrolides increases the risk of infantile hypertrophic pyloric stenosis Article

2014 Evidence-Based Medicine

12. Macrolides

Macrolides USE OF MACROLIDES IN PREGNANCY 0344 892 0909 USE OF MACROLIDES IN PREGNANCY (Date of issue: June 2017 , Version: 2.1 ) This is a UKTIS monograph for use by health care professionals. For case-specific advice please contact UKTIS on 0344 892 0909. To report an exposure please download and complete a . Please encourage all women to complete an . A corresponding patient information leaflet on is available at . Summary The macrolide antibiotics include azithromycin, clarithromycin (...) , erythromycin, spiramycin and telithromycin. Macrolides have an antibacterial spectrum similar to that of penicillin and are thus considered an alternative in penicillin-allergic patients. Indications include sinusitis, otitis media, pharyngitis, tonsillitis, bronchitis, skin and soft tissue infection. Azithromycin is also used in the treatment of chlamydia, and clarithromycin in the eradication of Helicobacter pylori . The considerable data for macrolides as a class, and for erythromycin specifically, do

2014 UK Teratology Information Service

13. Macrolide therapy for chronic rhinosinusitis: a meta-analysis

Macrolide therapy for chronic rhinosinusitis: a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2013 DARE.

14. Statin toxicity from macrolide antibiotic coprescription: a population-based cohort study. Full Text available with Trip Pro

Statin toxicity from macrolide antibiotic coprescription: a population-based cohort study. Clarithromycin and erythromycin, but not azithromycin, inhibit cytochrome P450 isoenzyme 3A4 (CYP3A4), and inhibition increases blood concentrations of statins that are metabolized by CYP3A4.To measure the frequency of statin toxicity after coprescription of a statin with clarithromycin or erythromycin.Population-based cohort study.Ontario, Canada, from 2003 to 2010.Continuous statin users older than 65

2013 Annals of Internal Medicine

15. Macrolides for diffuse panbronchiolitis. (Abstract)

Macrolides for diffuse panbronchiolitis. Diffuse panbronchiolitis (DPB) is a chronic airways disease predominantly affecting East Asians. Macrolides, a class of antibiotics, have been used as the main treatment for DPB, based on evidence from retrospective and non-randomised studies.To assess the efficacy and safety of macrolides for DPB.We searched CENTRAL 2012, Issue 7, MEDLINE (1966 to July week 2, 2012), EMBASE (1974 to July 2012), Chinese Biomedical Literature Database (CBM) (1978 to July (...) 2012), China National Knowledge Infrastructure (CNKI) (1974 to July 2012), KoreaMed (1997 to July 2012) and Database of Japana Centra Revuo Medicina (1983 to July 2012).Randomised controlled trials (RCTs) or quasi-RCTs assessing the effect of macrolides for DPB.Two review authors independently assessed study quality and subsequent risk of bias according to the Cochrane Collaboration's tool for assessing risk of bias. The primary outcomes were five-year survival rate, lung function and clinical

2013 Cochrane

16. Macrolide Antibiotics and Survival in Patients with Acute Lung Injury

Macrolide Antibiotics and Survival in Patients with Acute Lung Injury PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

2012 PedsCCM Evidence-Based Journal Club

17. The risk of hypotension following co-prescription of macrolide antibiotics and calcium-channel blockers Full Text available with Trip Pro

The risk of hypotension following co-prescription of macrolide antibiotics and calcium-channel blockers The macrolide antibiotics clarithromycin and erythromycin may potentiate calcium-channel blockers by inhibiting cytochrome P450 isoenzyme 3A4. However, this potential drug interaction is widely underappreciated and its clinical consequences have not been well characterized. We explored the risk of hypotension or shock requiring hospital admission following the simultaneous use of calcium (...) -channel blockers and macrolide antibiotics.We conducted a population-based, nested, case-crossover study involving people aged 66 years and older who had been prescribed a calcium-channel blocker between Apr. 1, 1994, and Mar. 31, 2009. Of these patients, we included those who had been admitted to hospital for the treatment of hypotension or shock. For each antibiotic, we estimated the risk of hypotension or shock associated with the use of a calcium blocker using a pair-matched analytic approach

2011 EvidenceUpdates

18. Macrolides for diffuse panbronchiolitis. (Abstract)

Macrolides for diffuse panbronchiolitis. Diffuse panbronchiolitis (DPB) is a chronic airways disease predominantly affecting East Asians. Macrolides, a class of antibiotics, have been used as the main treatment for DPB, based on evidence from retrospective and non-randomised studies.To assess the efficacy and safety of macrolides for DPB.We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2010, issue 1), which contains the Cochrane Acute Respiratory (...) Infections Group's Specialised Register, MEDLINE (1966 to April 2010), EMBASE (1974 to April 2010), Chinese Biomedical Literature Database (CBM) (1978 to April 2010), China National Knowledge Infrastructure (CNKI) (1974 to April 2010), KoreaMed (1997 to April 2010) and Database of Japana Centra Revuo Medicina (1983 to April 2010).Randomised controlled trials (RCTs) or quasi-RCTs assessing the effect of macrolides for DPB.Two review authors independently assessed study quality and subsequent risk of bias

2010 Cochrane

19. Increased clinical failures when treating acute otitis media with macrolides: a meta-analysis

Increased clinical failures when treating acute otitis media with macrolides: a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2010 DARE.

20. Effect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci in healthy volunteers: a randomised, double-blind, placebo-controlled study. (Abstract)

Effect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci in healthy volunteers: a randomised, double-blind, placebo-controlled study. Resistance to antibiotics is a major public-health problem, and studies that link antibiotic use and resistance have shown an association but not a causal effect. We used the macrolides azithromycin and clarithromycin to investigate the direct effect of antibiotic exposure on resistance in the oral streptococcal (...) flora of healthy volunteers.Volunteers were treated with azithromycin (n=74), clarithromycin (74), or placebo (76) in a randomised, double-blind trial. Pharyngeal swabs were obtained before and after administration of study treatment through 180 days. The proportion of streptococci that were macrolide resistant was assessed and the molecular basis of any change in resistance investigated. Analyses were done on an intent-to-treat basis. This study is registered with ClinicalTrials.gov, number

2007 Lancet Controlled trial quality: predicted high